Title

Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery
Evaluation of Post Hospital Administration of Celecoxib Following Minimally Invasive Knee Replacement Surgery: A Randomized Controlled Study
  • Phase

    Phase 4
  • Study Type

    Observational
  • Status

    Completed No Results Posted
  • Intervention/Treatment

    celecoxib ...
  • Study Participants

    107
This study will evaluate the benefits of continuing celecoxib through six weeks of total knee arthroplasty recovery. This is a randomized, double blind study with a group of approximately 130 primary total knee patients. All patients will receive celecoxib throughout their hospitalization as per current minimally invasive total knee arthroplasty protocol. At the time of hospital discharge, participating patients will be randomly placed on either celecoxib 200mg twice a day or a placebo twice a day.

This study will determine if the continued use of celecoxib for six weeks after total knee arthroplasty hospitalization will further decrease narcotic consumption, improve knee range of motion, improve ambulatory ability, and improve patient satisfaction over patients receiving celecoxib only during the acute hospitalization.
Study Started
Jun 30
2007
Primary Completion
Dec 31
2009
Study Completion
Dec 31
2009
Last Update
Apr 28
2016
Estimate

Drug Celecoxib

Population

total knee canidates

Criteria

Inclusion Criteria:

having undergone a minimally invasive total knee by select surgeon
voluntarily enrolled
independent community ambulators
only patients being discharged directly home

Exclusion Criteria:

celecoxib allergy or intolerence
Renal insufficiency (defined as serum creatine level >1.5 mg/dL or BUN level >22mg/dL
History of bleeding gastic or duodenal ulceration
New York Heart Association Class III or IV Congestive Heart Failure
Previous myocardial infarction or cerebralvascular event
Severe inflammatory bowel disease
Known coagulation abnormality or hepatic disease
Chronic coumadin administration
Refusal by primary or cardiac physician
No Results Posted